WO2023024337A1 - Use of thiazolyldiazonaphthol compound in preparation of drug for treating glioblastoma - Google Patents

Use of thiazolyldiazonaphthol compound in preparation of drug for treating glioblastoma Download PDF

Info

Publication number
WO2023024337A1
WO2023024337A1 PCT/CN2021/137746 CN2021137746W WO2023024337A1 WO 2023024337 A1 WO2023024337 A1 WO 2023024337A1 CN 2021137746 W CN2021137746 W CN 2021137746W WO 2023024337 A1 WO2023024337 A1 WO 2023024337A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolyldiazonaphthol
drug
preparation
formula
gbm
Prior art date
Application number
PCT/CN2021/137746
Other languages
French (fr)
Chinese (zh)
Inventor
畅君雷
余敏
胡小燕
杨时伦
Original Assignee
深圳先进技术研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳先进技术研究院 filed Critical 深圳先进技术研究院
Publication of WO2023024337A1 publication Critical patent/WO2023024337A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of a thiazolyldiazonaphthol compound represented by formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating glioblastoma (GBM), in formula I, R1, R2, R3, R4, R5, and R6 being selected from H or C1 - 5alkyl groups. The drug prepared from the thiazolyldiazonaphthol compound represented by formula I or the pharmaceutically acceptable salt thereof has small side effects, high targeting performance, and no obvious systemic toxicity, and can effectively inhibit and kill GBM cells, and has important prospects in the direction of chemotherapeutic drugs for GBM.
PCT/CN2021/137746 2021-08-27 2021-12-14 Use of thiazolyldiazonaphthol compound in preparation of drug for treating glioblastoma WO2023024337A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110994420.6A CN113616645A (en) 2021-08-27 2021-08-27 Application of thiazolyl diazo naphthol compound in preparation of medicine for treating malignant brain glioma
CN202110994420.6 2021-08-27

Publications (1)

Publication Number Publication Date
WO2023024337A1 true WO2023024337A1 (en) 2023-03-02

Family

ID=78388057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/137746 WO2023024337A1 (en) 2021-08-27 2021-12-14 Use of thiazolyldiazonaphthol compound in preparation of drug for treating glioblastoma

Country Status (2)

Country Link
CN (1) CN113616645A (en)
WO (1) WO2023024337A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113616645A (en) * 2021-08-27 2021-11-09 深圳先进技术研究院 Application of thiazolyl diazo naphthol compound in preparation of medicine for treating malignant brain glioma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459601A (en) * 2014-03-12 2017-02-22 亨利·M·杰克逊军事医学促进基金会 Novel inhibitors for erg oncogene positive cancers
US20180169074A1 (en) * 2015-09-10 2018-06-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Azophenols as ERG Oncogene Inhibitors
CN113616645A (en) * 2021-08-27 2021-11-09 深圳先进技术研究院 Application of thiazolyl diazo naphthol compound in preparation of medicine for treating malignant brain glioma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459601A (en) * 2014-03-12 2017-02-22 亨利·M·杰克逊军事医学促进基金会 Novel inhibitors for erg oncogene positive cancers
US20180169074A1 (en) * 2015-09-10 2018-06-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Azophenols as ERG Oncogene Inhibitors
CN113616645A (en) * 2021-08-27 2021-11-09 深圳先进技术研究院 Application of thiazolyl diazo naphthol compound in preparation of medicine for treating malignant brain glioma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AHMED A. MOHAMED, CHARLES P XAVIER, GAUTHAMAN SUKUMAR, SHYH-HAN TAN, LAKSHMI RAVINDRANATH, NISHAT SERAJ, VINEET KUMAR, TADURU L SR: "Identification of a small molecule that selectively inhibits ERG-positive cancer cell growth", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, US, pages canres.2949.2017, XP055677968, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-17-2949 *
HSING MICHAEL, WANG YUZHUO, RENNIE PAUL S., COX MICHAEL E., CHERKASOV ARTEM: "ETS transcription factors as emerging drug targets in cancer", MEDICINAL RESEARCH REVIEWS, WILEY SUBSCRIPTION SERVICES, INC., A WILEY COMPANY, US, vol. 40, no. 1, 1 January 2020 (2020-01-01), US , pages 413 - 430, XP093038519, ISSN: 0198-6325, DOI: 10.1002/med.21575 *
READ RENEE D., FENTON TIM R., GOMEZ GERMAN G., WYKOSKY JILL, VANDENBERG SCOTT R., BABIC IVAN, IWANAMI AKIO, YANG HUIJUN, CAVENEE W: "A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma", PLOS GENETICS, vol. 9, no. 2, 14 February 2013 (2013-02-14), pages e1003253, XP093038524, DOI: 10.1371/journal.pgen.1003253 *
SONG YUNNONG, LI CHENG, JIN LEI, XING JINGSONG, SHA ZHUANG, ZHANG TONG, JI DAOFEI, YU RUTONG, GAO SHANGFENG: "RIOK2 is negatively regulated by miR‐4744 and promotes glioma cell migration/invasion through epithelial‐mesenchymal transition", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, UNIVERSITY PRESS CAROL DAVILA, BUCHAREST, RO, vol. 24, no. 8, 1 April 2020 (2020-04-01), RO , pages 4494 - 4509, XP093038518, ISSN: 1582-1838, DOI: 10.1111/jcmm.15107 *
YU MIN, HU XIAOYAN, YAN JINGYU, WANG YING, LU FEI, CHANG JUNLEI: "RIOK2 Inhibitor NSC139021 Exerts Anti-Tumor Effects on Glioblastoma via Inducing Skp2-Mediated Cell Cycle Arrest and Apoptosis", BIOMEDICINES, vol. 9, no. 9, 1 January 2021 (2021-01-01), pages 1244 - 86, XP093038527, DOI: 10.3390/biomedicines9091244 *

Also Published As

Publication number Publication date
CN113616645A (en) 2021-11-09

Similar Documents

Publication Publication Date Title
US5728735A (en) Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient
AU681321B2 (en) Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
TNSN04213A1 (en) High drug load tablet
EP1156045A4 (en) Amide derivatives and drug compositions
HUP0105231A2 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents and medicaments containing the compounds
NO20055655L (en) Use of azetidinecarboxamide derivatives in therapy
JP2008503533A5 (en)
JP2012505879A5 (en)
WO2023024337A1 (en) Use of thiazolyldiazonaphthol compound in preparation of drug for treating glioblastoma
JP2008531585A5 (en)
CY1119188T1 (en) Antimicrobial Preservatives for the Achievement of Multiple-Dose Pharmaceuticals Using Beta-Cyclo-Extrinsic Liquids
CA2626767A1 (en) Heterocyclic substituted pyridine derivatives and antifungal agent containing same
EP0092391A3 (en) Novel piperidine derivatives and pharmaceutical compositions containing same
WO2002089782A3 (en) Dioxanes and uses thereof
MX2022013865A (en) Synthetic lipid-like materials for brain delivery.
HRP20120002T1 (en) Treatment of mastitis
Bailly Medicinal applications and molecular targets of dequalinium chloride
DE69222698D1 (en) 4-DESOXY-4-EPIPODOPHYLLOTOXIN DERIVATIVES OR THEIR PHARMACEUTICAL ACCEPTABLE SALTS
EP1224932A4 (en) Drugs inhibiting cell death
SE0002476D0 (en) New compounds
WO2024100452A3 (en) Heterocyclic compounds as sting agonists
MX2022010673A (en) New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them.
IE32509B1 (en) Naphthacene derivatives
CA2441309A1 (en) Biguanide derivatives
CA2410160C (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21954853

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21954853

Country of ref document: EP

Kind code of ref document: A1